BMJ Open Risk factors and clinical outcomes of functional decline during hospitalisation in very old patients with acute decompensated heart failure: an observational study

Hidenori Yaku,^{1,2} Takao Kato ⁽¹⁾,¹ Takeshi Morimoto ⁽¹⁾,³ Yasutaka Inuzuka,⁴ Yodo Tamaki,⁵ Neiko Ozasa,¹ Erika Yamamoto,¹ Yusuke Yoshikawa,¹ Takeshi Kitai,⁶ Masashi Kato,² Tomoyuki Ikeda,⁷ Yutaka Furukawa,⁶ Yoshihisa Nakagawa,⁸ Yukihito Sato,⁹ Koichiro Kuwahara,¹⁰ Takeshi Kimura¹

ABSTRACT

Morimoto T, et al. Risk factors and clinical outcomes of functional decline during hospitalisation in very old patients with acute decompensated heart failure: an observational study. BMJ Open 2020;10:e032674. doi:10.1136/ bmjopen-2019-032674

To cite: Yaku H, Kato T,

Prepublication history and additional material for this paper are available online. To view these files, please visit the journal online (http://dx.doi. org/10.1136/bmjopen-2019-032674).

Received 03 July 2019 Revised 02 December 2019 Accepted 17 January 2020



C Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BM.J.

For numbered affiliations see end of article.

Correspondence to Dr Takao Kato:

tkato75@kuhp.kyoto-u.ac.jp

Objective To investigate the prevalence and risk factors of functional decline during hospitalisation and its relationship with postdischarge outcomes in very old patients with acute decompensated heart failure (ADHF) hospitalisation.

Design Prospective cohort study between 1 October 2014 and 31 March 2016.

Setting A physician-initiated, multicentre study of consecutive patients admitted for ADHF in 19 hospitals throughout Japan.

Participants Among 3555 patients hospitalised for ADHF (median age (IQR), 80 (71-86) years; 1572 (44%) women), functional decline during the index hospitalisation occurred in 528 patients (15%).

Primary and secondary outcomes The primary outcome measure was a composite of all-cause death or heart failure (HF) hospitalisation after discharge. The secondary outcome measures were all-cause death, HF hospitalisation, and a composite of all-cause death or allcause hospitalisation.

Results The independent risk factors for functional decline included age ≥80 years (OR 2.71; 95% CI 2.09 to 3.51), female (OR 1.32; 95% Cl 1.05 to 1.67), prior stroke (OR 1.67; 95% CI 1.28 to 2.19), dementia (OR 2.26; 95% Cl 1.74 to 2.95), ambulatory before admission (OR 1.74; 95% Cl 1.29 to 2.35), elevated body temperature (OR 1.91; 95% CI 1.31 to 2.79), New York Heart Association class III or IV on admission (OR 1.54; 95% CI 1.07 to 2.22), decreased albumin levels (OR 1.76; 95% CI 1.32 to 2.34), hyponatraemia (OR 1.49; 95% CI 1.10 to 2.03) and renal dysfunction (OR 1.55; 95% CI 1.22 to 1.98), after multivariable adjustment. The cumulative 1-year incidence of the primary outcome in the functional decline group was significantly higher than that in the no functional decline group (50% vs 31%, log-rank p<0.001). After adjusting for baseline characteristics, the higher risk of the functional decline group relative to the no functional decline group remained significant (adjusted HR 1.46; 95% Cl 1.24 to 1.71; p<0.001).

Strengths and limitations of this study

- This study is the first, large-scale, contemporary, multicentre, observational study reporting the prevalence of functional decline in very old patients hospitalised for acute decompensated heart failure (ADHF).
- The data for this study were prospectively collected from consecutive patients who had hospital admission due to ADHF in the real-world clinical practice in Japan.
- This study examines the risk factors of functional decline in very old patients hospitalised for ADHF and whether functional decline during the index hospitalisation was associated with worse postdischarge outcomes.
- We did not collect data regarding on-site and outpatient rehabilitation and nutritional support.

Conclusions Independent risk factors of functional decline in very old patients with ADHF were related to both frailty and severity of HF. Functional decline during ADHF hospitalisation was associated with unfavourable postdischarge outcomes.

Trial registration number NCT02334891, UMIN000015238.

INTRODUCTION

Functional decline in hospitalised patients is a complex and dynamic process.¹⁻³ Functional decline during hospitalisation was reported to occur in approximately 30%-50% of patients hospitalised for acute medical illness.²⁴⁵ In the rapidly ageing societies, the number of very old patients hospitalised for acute decompensated heart failure (ADHF) is increasing, and ADHF has become the leading cause of hospitalisation due to acute

BMJ



Figure 1 Patient flow chart. ADHF, acute decompensated heart failure; KCHF, Kyoto Congestive Heart Failure.

medical illness. In older patients, functional decline associated with hospitalisation often leads to subsequent inability to live actively and independently.

However, there is a scarcity of data regarding the risk factors of functional decline in very old patients hospitalised for ADHF. Identifying high-risk patients for functional decline during hospitalisation would be useful for its prevention. Furthermore, no previous study has focused on subsequent clinical outcomes in patients with functional decline during hospitalisation. Therefore, we sought to clarify the risk factors for functional decline during hospitalisation in very old patients with ADHF and to compare the 1-year clinical outcomes between the two groups of patients with and without functional decline during hospitalisation for ADHF in a large Japanese observational database of hospitalised patients for ADHF in the real-world clinical practice.

METHODS

Study design, setting and population

The Kyoto Congestive Heart Failure (KCHF) registry is a physician-initiated, prospective, observational, multicentre cohort study that enrolled consecutive patients who were hospitalised for ADHF for the first time between 1 October 2014 and 31 March 2016. These patients were admitted into 19 secondary and tertiary hospitals, including rural and urban as well as large and small institutions, throughout Japan. The study met the conditions of the Japanese ethical guidelines for epidemiological study and the US policy for protecting human research participants.^{6 7} This study followed the Strengthening the Reporting of Observational Studies in Epidemiology reporting guideline.

The details of the KCHF study design and patient enrolment are described elsewhere.^{8–11} Briefly, we enrolled all patients with ADHF, as defined by the modified Framingham criteria, who were admitted to the participating hospitals and patients who underwent heart failurespecific treatment involving intravenous drugs within 24 hours after hospital presentation. Patient records were anonymised before analysis. Data analysis was conducted from August 2018 to October 2018.

Among 4056 patients enrolled in the KCHF registry, 3785 patients were discharged alive after hospitalisation for ADHF. Clinical follow-up data were collected in October 2017. The attending physicians or research assistants at each participating hospital collected clinical events after the index hospitalisation from hospital charts or by contacting patients, their relatives or their referring physicians with consent. The present analysis had two objectives. First, we sought to clarify the risk factors for functional decline during hospitalisation of patients with ADHF. Second, we sought to compare the 1-year clinical outcomes between the two groups of patients with and without functional decline during the hospitalisation for ADHF. Among 4056 patients enrolled in the KCHF registry, the current study population consisted of 3555 patients who were discharged alive and were assessed for functional decline during hospitalisation, excluding 271 patients who died during the index hospitalisation, 99 patients whose functional status before admission and/or at discharge was not available, and 131 patients who were bedridden before index hospitalisation (figure 1). The long-term follow-up was censored at 1 year. The primary outcome measure in the current analysis was a composite of all-cause death or heart failure hospitalisation at 1 year. The secondary outcome measures were all-cause death, heart failure hospitalisation, and a composite of all-cause death or all-cause hospitalisation at 1 year.

Definitions

Physical activity before admission and at discharge was classified by mobility status based on the definition of the Japanese long-term care insurance into ambulatory (including those patients using any aid such as stick), use of wheelchair outdoor only, use of wheelchair indoor and outdoor, and bedridden state.8 Functional decline was defined as the decline of at least one stage on physical activity at discharge compared with preadmission status. In-hospital worsening heart failure was defined as additional intravenous drug administration for heart failure, haemodialysis, or mechanical circulatory or respiratory support, occurring >24 hours after therapy initiation.¹² In-hospital worsening renal function was defined as >0.3 mg/dL increase in serum creatinine levels during the index hospitalisation.¹³⁻¹⁵ Detailed definitions of baseline clinical characteristics including the signs and symptoms of heart failure have been described previously.⁹ Missing values are presented in online supplementary eTable 1.

Statistical analysis

Categorical variables were presented as numbers with percentages and compared using χ^2 test. Continuous variables were expressed as mean with SD or median with 25th–75th percentiles, and compared using the Student's t-test when normally distributed or Wilcoxon rank-sum test when not normally distributed.

We compared baseline characteristics and clinical outcomes based on the presence or absence of functional decline during the index hospitalisation. A multivariable logistic regression model was developed to identify clinical characteristics associated with an increased risk for functional decline. We used 24 clinically relevant factors listed in table 1 as potential independent risk factors in multivariable logistic regression models and estimated the OR and 95% CI. We used the Kaplan-Meier method to estimate the cumulative 1-year incidences of the outcome measures and assessed the differences with the log-rank test. We expressed the associations of the functional decline group with the no functional decline group for all outcome measures as HR with 95% CI by multivariable Cox proportional hazard models, incorporating 30 clinically relevant risk-adjusting variables indicated in table 1. We also conducted subgroup analyses stratified by age, sex, left ventricular ejection fraction (LVEF), anaemia, albumin levels, body temperature and the symptomatic status at discharge (oedema and general malaise at discharge). In the multivariable analysis and subgroup analyses, continuous variables were dichotomised by clinically meaningful reference values or median values: age \geq 80 years based on the median value, LVEF <40% based on the heart failure guideline of LVEF classification,¹⁶ body mass index $\leq 22 \text{ kg/m}^2$, renal dysfunction (estimated glomerular filtration rate $<30 \,\mathrm{mL}/\mathrm{min}/1.73 \,\mathrm{m}^2$) based on chronic kidney disease grade, decreased albumin levels (serum albumin <3.0 g/dL), hyponatraemia (serum sodium <135 mEq/L), and elevated body temperature (body temperature $\geq 37.5^{\circ}$ C) based on the cut-off value in metabolic syndrome.¹⁷

We performed an additional analysis including data of those patients who died during the index hospitalisation and those who were bedridden before the index hospitalisation, and evaluated the factors associated with functional decline or in-hospital mortality by constructing the multivariable adjusted Cox models. All statistical analyses were conducted by a physician (HY) and a statistician (TM) using JMP V.13.0 or SAS V.9.4. Two-tailed p values less than 0.05 were considered statistically significant.

Patient and public involvement

No patients were involved.

RESULTS

Baseline clinical characteristics

Among 3555 study patients, physical activity before admission included ambulatory in 2949 patients (83%), use of wheelchair outdoor only in 272 patients (7.7%), and use of wheelchair outdoor and indoor in 334 patients (9.4%). At hospital discharge, functional decline was observed in 420 patients (14%) who were ambulatory before admission, in 80 patients (29%) who had used wheelchair outdoor only, and in 28 patients (8.4%) who had used wheelchair outdoor and indoor. Consequently, decline in functional status was observed in 528 patients (15%; functional decline group), while functional decline was not observed in 3027 patients (85%; no functional decline group) (online supplementary eFigure 1). Use of wheelchair outdoor only before admission was more prevalent in the functional decline group than in the no functional decline group; however, 80% of patients in the functional decline group were ambulatory before admission (table 1).

Regarding the baseline clinical characteristics, the patients in the functional decline group were older and had a higher prevalence of hypertension, prior stroke, renal dysfunction, dementia, malignancy, anaemia, decreased albumin levels and hyponatraemia (table 1). There were no significant differences in previous heart failure hospitalisation, atrial fibrillation or flutter, previous myocardial infarction, chronic lung disease, and living alone status as a social background between the two groups (table 1). The functional decline group was more likely to have a valvular aetiology, lower blood pressure, lower heart rate, higher levels of brain natriuretic peptide (BNP) or N-terminal portion of proBNP, and a higher LVEF (table 1). The proportion of patients who achieved relief of signs and symptoms on admission after treatment in the emergency room was not significantly different between the two groups (14% vs 16%, p=0.25).

Risk factors for functional decline

Among the baseline characteristics and status on hospital presentation, the following independent risk factors for functional decline during hospitalisation were identified by the multivariable logistic regression analysis: age \geq 80 years (OR 2.71; 95% CI 2.09 to 3.51), female (OR 1.32; 95% CI 1.05 to 1.67), prior stroke (OR 1.67; 95% CI 1.28 to 2.19), dementia (OR 2.26; 95% CI 1.74 to 2.95), ambulatory before admission (OR 1.74; 95% CI 1.29 to 2.35), elevated body temperature (OR 1.91; 95% CI 1.31 to 2.79), New York Heart Association class III or IV on admission (OR 1.54; 95% CI 1.07 to 2.22), decreased albumin levels (OR 1.76; 95% CI 1.32 to 2.34), hyponatraemia (OR 1.49; 95% CI 1.10 to 2.03) and renal dysfunction (OR 1.55; 95% CI 1.22 to 1.98) (figure 2).

In-hospital adverse events and status at discharge

The median length of hospital stay was longer in the functional decline group than in the no functional decline group (21 days vs 15 days, p<0.001). Regarding in-hospital adverse events, the prevalence of worsening heart failure, worsening renal function and stroke was higher in the functional decline group than in the no functional decline group (table 2). The proportion of patients with symptoms such as oedema and general malaise at discharge was higher in the functional decline group than in the no functional decline group (table 1). Consequently, the proportion of patients in the functional decline group discharged to home was also lower (47% vs 90%, p<0.001). Regarding medical treatment at discharge, ACE inhibitor or angiotensin receptor blocker, and beta blocker were less often prescribed in the functional decline group than in the no functional decline group (table 1).

Interfact and define Not functional define nsize nsize Not functional define App. yans 85 (80-89) 79 (70-85) 4.001 >80 years^1 399 (66) 1276 (42) 4.001 >20 years^1 294 (66) 1276 (42) 4.001 >22 bards 1278 (42) 4.001 22.04.00 22.14.45 4.001 >22 bards 128 (43) -2.001 22.04.01 22.04.01 22.04.01 20.01 Medical hintory 126 (36) 1077 (36) 0.92 Athal fibrillation of futter 220.42 1263 (42) 0.98 Hypertension*1 108 (36) 1077 (36) 0.22 0.021 Diaboles mellius*1 118 (38) 0.29 0.021 0.021 Mocardial infraction*1 126 (34) 402 (14) 40.01 0.011 Stroke*1 127 (24) 681 (23) 0.011 0.011 Minigramsy 797 (18) 427 (18.2) 4.02 0.001 Stroke*1 176 (33) 428 (18) 0.001	Table 1 Patient characteristics				
n=323 n=3627 P Value Age, yans 56 (90-26) 76 (70-26) <0.001 >80 yans 1 369 (76) 1407 (46) <0.001 >80 yans 1 226 (45) 1276 (42) <0.001 BM, kgym ² 22.0-4.0 23.144.5 <0.001 System 226 (55) 128 (42) 0.98 Medical history Hear falue hospitalisation 1 180 (56) 1077 (35) 0.92 Arial fibriliton or futter 220 (42) 1263 (42) 0.98 Hypertension 1 187 (55) 1145 (28) 0.29 Myscardial Infaction 1 112 (21) 681 (23) 0.51 Stroket 1 125 (24) 432 (14) <0.001 Maignaney 97 (15) 419 (14) 0.006 Chronic lung disease 1 175 (33) 423 (14) <0.001 Social background on admission Poor medical adherence 120 (19) 438 (15) 0.22 Public assistance		Functional decline	No functional decline		
Chinea characteristics Age, yans \$ 85 (80–89) 79 (70–85) <.0.011 90 yans 1 Age, yans 2 Age, yans 2 Age, yans 4 Step (42) 40.001 Women 1 22 (42) 1278 (42) <.0.001 322 kg/m ² 1 220 (42) 1283 (44) <.0.001 322 kg/m ² 1 220 (42) 1283 (42) 0.93 Head failure hospitalisation 1 Hord failure hospitalisation 1 Carearchy smoking 1 Antion disease 1 Hord failure disease 1 Hord		n=528	n=3027	P value	
App. years B5 (80-B9) // ((C-B5) <.0001 380 years*1 399 (76) 1407 (46) <.0001	Clinical characteristics	0.5 (0.0 . 0.0)			
389 (rb) 140 / 149 c.0.001 Women*† 294 (66) 1278 (42) <0.001	Age, years	85 (80–89)	79 (70–85)	<0.001	
Women*f 294 (66) 12.78 (42) <0.001	≥80 years*†	399 (76)	1407 (46)	<0.001	
BM, Kg/m ² + 22 64.0 23 14.5 <.0001	Women*†	294 (56)	1278 (42)	<0.001	
3.25 kg/m ⁴⁺ ↑ 268 (5) 1.28 (44) <0.011	BMI, kg/m ²	22.0±4.0	23.1±4.5	<0.001	
Medical history Heart failure hospitalisation*† 186 (36) 1077 (36) 0.92 Arial fibrillation or flutter 220 (42) 1263 (42) 0.98 Hypertension*† 406 (77) 2174 (72) 0.02 Diabetes mellitas*† 187 (35) 1145 (38) 0.29 Myocardial infarction*† 112 (21) 681 (23) 0.51 Stroke*† 128 (24) 432 (14) -0.001 Currently smoking*† 28 (5.5) 425 (14) -0.001 Maignancy 97 (19) 419 (14) 0.006 Chronic lung disease*† 41 (7.8) 4247 (8.2) 0.76 Dementia*† 127 (24) 652 (22) 0.20 Poor medical adherence 100 (19) 498 (16) 0.16 Living alone*† 127 (24) 652 (22) 0.20 Public assistance 24 (4.6) 186 (6.1) 0.14 Functional status before admission 420 (80) 2529 (84) 0.02 Use of wheelchair (outdoor only) 80 (15) 122 (6.3) -0.001 Orgin <td>≤22 kg/m²*†</td> <td>269 (55)</td> <td>1281 (44)</td> <td><0.001</td>	≤22 kg/m ² *†	269 (55)	1281 (44)	<0.001	
Hear failure hospitalization*† 186 (36) 1077 (36) 0.32 Artial fibrillation or flutter 220 (42) 1268 (42) 0.98 Hypertension*† 406 (77) 2174 (72) 0.02 Diabetes mellitus*† 187 (35) 1145 (38) 0.29 Myocardial infarction*† 187 (35) 1145 (38) 0.29 Myocardial infarction*† 187 (35) 425 (14) <0.001	Medical history				
Arial fibrilation or fluter 220 (42) 1283 (42) 0.98 Hypertension*† 406 (77) 1274 (72) 0.02 Diabetes melitus*† 187 (35) 1145 (38) 0.29 Myocardial infarction*† 112 (21) 681 (23) 0.51 Stroke*† 28 (5.5) 425 (14) <0.001	Heart failure hospitalisation*†	186 (36)	1077 (36)	0.92	
Hypertension*† 406 (7) 2174 (72) 0.02 Diabetes melitus*† 187 (35) 1145 (38) 0.29 Myocardial infarction*† 112 (21) 681 (23) 0.51 Stroke*† 28 (5.5) 425 (14) <0.001	Atrial fibrillation or flutter	220 (42)	1263 (42)	0.98	
Diabetes melitius*† 187 (35) 1145 (38) 0.29 Myocardial infarction*† 112 (21) 681 (23) 0.51 Stroke*† 125 (24) 432 (14) -0.001 Currently smoking*† 28 (5.5) 425 (14) -0.001 Maignancy 97 (18) 419 (14) 0.006 Chronic lung disease*† 41 (7.8) 247 (8.2) 0.76 Dementia* 175 (33) 423 (14) -0.001 Social background on admission - - 0.01 Social background on admission - - 0.02 0.20 Public assistance 24 (4.6) 186 (6.1) 0.14 - Functional status before admission - - - - Use of wheelchair (outdoor only) 80 (15) 192 (6.3) -0.001 Use of wheelchair (outdoor only) 80 (15) 192 (6.5) 0.22 Hypertensive 131 (25) 754 (25) 0.96 Valviar 124 (23) 565 (19) -0.001 Vial signa and symptoms on	Hypertension*†	406 (77)	2174 (72)	0.02	
Myocardial infarction*† 112 (21) 681 (23) 0.51 Stroka*† 125 (24) 432 (14) <0.001	Diabetes mellitus*†	187 (35)	1145 (38)	0.29	
Stroke*† 125 (24) 432 (14) <0.001	Myocardial infarction*†	112 (21)	681 (23)	0.51	
Currently smoking*† 28 (5.5) 425 (14) -0.001 Mailgnancy 97 (18) 419 (14) 0.006 Chronic lung disease*† 11 (7.8) 247 (8.2) 0.76 Dementia*† 175 (33) 423 (14) -0.001 Social background on admission 100 (19) 498 (16) 0.16 Living alone*† 127 (24) 652 (22) 0.20 Public assistance 24 (4.6) 186 (6.1) 0.14 Functional status before admission	Stroke*†	125 (24)	432 (14)	<0.001	
Mailgnancy 97 (18) 419 (14) 0.006 Chronic lung disease*↑ 417 (7.8) 247 (8.2) 0.76 Dementia*↑ 175 (33) 423 (14) <0.001	Currently smoking*†	28 (5.5)	425 (14)	<0.001	
Chronic lung disease*† 41 (7.8) 247 (8.2) 0.76 Dementia*† 175 (33) 421 (1.2) <0.001	Malignancy	97 (18)	419 (14)	0.006	
Dementia*† 175 (33) 423 (14) <0.001 Social background on admission <0001	Chronic lung disease*†	41 (7.8)	247 (8.2)	0.76	
Social background on admission Poor medical adherence 100 (19) 498 (16) 0.16 Living alone*† 127 (24) 652 (22) 0.20 Public assistance 24 (4.6) 186 (6.1) 0.14 Functional status before admission 420 (80) 2529 (84) 0.02 Use of wheelchair (outdoor only) 80 (15) 192 (6.3) <0.001	Dementia*†	175 (33)	423 (14)	<0.001	
Poor medical adherence 100 (19) 498 (16) 0.16 Living alone*† 127 (24) 652 (22) 0.20 Public assistance 24 (4.6) 186 (6.1) 0.14 Functional status before admission 420 (80) 2529 (84) 0.02 Use of wheelchair (outdoor only) 80 (15) 192 (6.3) <0.001	Social background on admission				
Living alone*† 127 (24) 652 (22) 0.20 Public assistance 24 (4.6) 186 (6.1) 0.14 Functional status before admission 420 (80) 2529 (84) 0.02 Ambulatory*† 420 (80) 2529 (84) <0.02	Poor medical adherence	100 (19)	498 (16)	0.16	
Public assistance 24 (4.6) 186 (6.1) 0.14 Functional status before admission	Living alone*†	127 (24)	652 (22)	0.20	
Functional status before admission Ambulatory*† 420 (80) 2529 (84) 0.02 Use of wheelchair (outdoor only) 80 (15) 192 (6.3) <0.001	Public assistance	24 (4.6)	186 (6.1)	0.14	
Ambulatory*† 420 (80) 2529 (84) 0.02 Use of wheelchair (outdoor only) 80 (15) 192 (6.3) <0.001	Functional status before admission				
Use of wheelchair (outdoor only) 80 (15) 192 (6.3) <0.001 Use of wheelchair (outdoor and indoor) 28 (5.3) 306 (10) <0.001	Ambulatory*†	420 (80)	2529 (84)	0.02	
Use of wheelchair (outdoor and indoor) 28 (5.3) 306 (10) <0.001 Origin Ischaemic 134 (25) 820 (27) 0.41 Acute coronary syndrome*† 36 (6.8) 166 (5.5) 0.22 Hypertensive 131 (25) 754 (25) 0.96 Valvular 124 (23) 565 (19) <0.001	Use of wheelchair (outdoor only)	80 (15)	192 (6.3)	<0.001	
Origin Ischaemic 134 (25) 820 (27) 0.41 Acute coronary syndrome*† 36 (6.8) 166 (5.5) 0.22 Hypertensive 131 (25) 754 (25) 0.96 Valvular 124 (23) 565 (19) <0.001	Use of wheelchair (outdoor and indoor)	28 (5.3)	306 (10)	<0.001	
Ischaemic 134 (25) 820 (27) 0.41 Acute coronary syndrome*† 36 (6.8) 166 (5.5) 0.22 Hypertensive 131 (25) 754 (25) 0.96 Valvular 124 (23) 565 (19) <0.001	Origin				
Acute coronary syndrome*† 36 (6.8) 166 (5.5) 0.22 Hypertensive 131 (25) 754 (25) 0.96 Valvular 124 (23) 565 (19) <0.001	Ischaemic	134 (25)	820 (27)	0.41	
Hypertensive 131 (25) 754 (25) 0.96 Valvular 124 (23) 565 (19) <0.001	Acute coronary syndrome*†	36 (6.8)	166 (5.5)	0.22	
Valvular 124 (23) 565 (19) <0.001 Cardiomyopathy 54 (10) 492 (16) <0.001	Hypertensive	131 (25)	754 (25)	0.96	
Cardiomyopathy 54 (10) 492 (16) <0.001 Vital signs and symptoms on presentation BP, mm Hg BP, mm Hg Systolic BP 144±32 149±35 0.003 Systolic BP ≥140mm Hg 275 (53) 1741 (58) 0.03 0.03 Systolic BP ≥140mm Hg 275 (53) 1741 (58) 0.03 Systolic BP <90mm Hg*†	Valvular	124 (23)	565 (19)	<0.001	
Vital signs and symptoms on presentation BP, mm Hg Systolic BP 144±32 149±35 0.003 Systolic BP ≥140mm Hg 275 (53) 1741 (58) 0.03 Systolic BP <90mm Hg*†	Cardiomyopathy	54 (10)	492 (16)	<0.001	
BP, mm Hg Systolic BP 144±32 149±35 0.003 Systolic BP ≥140 mm Hg 275 (53) 1741 (58) 0.03 Systolic BP <90 mm Hg*†	Vital signs and symptoms on presentation				
Systolic BP144±32149±350.003Systolic BP ≥140 mm Hg275 (53)1741 (58)0.03Systolic BP <90 mm Hg*†	BP, mm Hg				
Systolic BP \geq 140 mm Hg275 (53)1741 (58)0.03Systolic BP $<$ 90 mm Hg*†12 (2.3)76 (2.5)0.76Diastolic BP81 \pm 2386 \pm 24<0.001	Systolic BP	144±32	149±35	0.003	
Systolic BP <90 mm Hg*† 12 (2.3) 76 (2.5) 0.76 Diastolic BP 81±23 86±24 <0.001	Systolic BP ≥140 mm Hg	275 (53)	1741 (58)	0.03	
Diastolic BP 81 ± 23 86 ± 24 <0.001Heart rate, beats/min 93 ± 27 96 ± 28 0.001 <60 beats/min*†	Systolic BP <90 mm Hg*†	12 (2.3)	76 (2.5)	0.76	
Heart rate, beats/min 93 ± 27 96 ± 28 0.001 <60 beats/min*†	Diastolic BP	81±23	86±24	<0.001	
<60 beats/min*†	Heart rate, beats/min	93±27	96±28	0.001	
Body temperature, °C 36.6±0.7 36.5±0.6 <0.001 ≥37.5 °C*† 58 (11) 154 (5.3) <0.001	<60 beats/min*†	44 (8.5)	195 (6.5)	0.11	
≥37.5 °C*† 58 (11) 154 (5.3) <0.001 Rhythms on presentation 280 (53) 1715 (57) 0.12 Atrial fibrillation or flutter*† 198 (38) 1085 (36) 0.47 NYHA class III or IV*† 482 (92) 2598 (73) <0.001	Body temperature, °C	36.6±0.7	36.5±0.6	<0.001	
Rhythms on presentation 280 (53) 1715 (57) 0.12 Atrial fibrillation or flutter*† 198 (38) 1085 (36) 0.47 NYHA class III or IV*† 482 (92) 2598 (73) <0.001	≥37.5 °C*†	58 (11)	154 (5.3)	<0.001	
Sinus rhythm 280 (53) 1715 (57) 0.12 Atrial fibrillation or flutter*† 198 (38) 1085 (36) 0.47 NYHA class III or IV*† 482 (92) 2598 (73) <0.001	Rhythms on presentation				
Atrial fibrillation or flutter*† 198 (38) 1085 (36) 0.47 NYHA class III or IV*† 482 (92) 2598 (73) <0.001	Sinus rhythm	280 (53)	1715 (57)	0.12	
NYHA class III or IV*† 482 (92) 2598 (73) <0.001 Tests on admission	Atrial fibrillation or flutter*†	198 (38)	1085 (36)	0.47	
Tests on admission	NYHA class III or IV*+	482 (92)	2598 (73)	<0.001	
	Tests on admission				

6

	Functional decline	No functional decline	
	n=528	n=3027	P value
LVEF	48±16	46±16	0.02
HFrEF (EF <40%)*†	167 (32)	1148 (38)	0.006
HFmrEF (EF 40%–49%)	117 (22)	566 (19)	0.06
HFpEF (EF ≥50%)	242 (46)	1305 (43)	0.24
Haemoglobin, g/L	110±21	117±24	<0.001
Anaemia*†‡	401 (76)	1946 (64)	< 0.001
BNP, pg/mL	782 (448–1410)	687 (375–1214)	<0.001
NT-proBNP, pg/mL	10 795 (3450–18000)	5416 (2629–11438)	0.001
Creatinine, mg/dL	1.2 (0.8–1.6)	1.1 (0.8–1.6)	0.21
eGFR, mL/min/1.73 m ²	38 (24–54)	46 (30–62)	<0.001
<30 mL/min/1.73 m ² *†	195 (37)	747 (25)	< 0.001
Blood urea nitrogen, mg/dL	28 (20–39)	23 (17–33)	<0.001
Albumin, g/dL	3.3±0.5	3.5±0.5	< 0.001
<3.0 g/dL*†	112 (22)	332 (11)	<0.001
Sodium, mEq/L	138±4.7	139±4.1	<0.001
<135 mEq/L*†	83 (16)	325 (11)	0.001
Potassium, mEq/L	4.3±0.8	4.2±0.6	0.03
Clinical signs and symptoms at discharge			
Oedema†	89 (17)	320 (11)	< 0.001
General malaise†	152 (31)	388 (14)	<0.001
Medications at discharge			
Number of drugs prescribed	8 (6–11)	9 (6–11)	0.12
Loop diuretics†	428 (81)	2472 (82)	0.74
ACEI or ARB†	242 (46)	1838 (61)	< 0.001
MRA†	208 (39)	1409 (47)	0.002
Beta blocker†	287 (54)	2101 (69)	< 0.001
Tolvaptan	76 (14)	299 (9.9)	0.002
Functional status at discharge			
Ambulatory	0	2682 (89)	<0.001
Use of wheelchair (outdoor only)	184 (35)	160 (5.3)	<0.001
Use of wheelchair (outdoor and indoor)	261 (49)	185 (6.1)	< 0.0001
Bedridden	83 (16)	0	<0.001
Living place after discharge			
Home	247 (47)	2709 (90)	<0.001
Hospital	225 (43)	180 (6.0)	< 0.001
Institution for the aged	50 (9.5)	114 (3.8)	<0.001
Other	4 (0.8)	17 (0.6)	0.59

Continuous variables are presented as mean±SD or median with (IQR). Categorical variables are presented as number (percentage).

*Risk-adjusting variables were selected for multivariable logistic regression models.

†Risk-adjusting variables were selected for multivariable Cox proportional hazard models.

 \pm Defined by the WHO criteria (haemoglobin <12 g/dL for women and <13 g/dL for men).

ACEI, ACE inhibitor; ARB, angiotensin receptor blocker; BMI, body mass index; BNP, brain-type natriuretic peptide; BP, blood pressure; EF, ejection fraction; eGFR, estimated glomerular filtration rate; HFmrEF, heart failure with mid-range ejection fraction; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; LVEF, left ventricular ejection fraction; MRA, mineralocorticoid receptor antagonist; NT-proBNP, N-terminal-proBNP; NYHA, New York Heart Association.

Long-term outcomes: functional decline versus no functional decline groups

1-year incidence of the primary outcome measure (a composite of all-cause death or heart failure hospitalisation) in the functional decline group was significantly

Variables		Unadjusted OR	P Value		Adjusted OR	P Value
Age ≥80 years	—	3.56 (2.88–4.40)	<0.001		2.71 (2.09–3.51)	<0.001
Women		1.72 (1.43–2.07)	<0.001		1.32 (1.05–1.67)	0.02
BMI ≤22		1.59 (1.31–1.93)	<0.001	—	1.21 (0.97–1.51)	0.10
Prior HF hospitalisation	-	0.99 (0.82–1.20)	0.92	-	0.84 (0.66–1.06)	0.13
Acute coronary syndrome	•	1.26 (0.87–1.83)	0.22		1.52 (0.96–2.40)	0.08
Hypertension		1.30 (1.05–1.62)	0.02		1.10 (0.84–1.43)	0.50
Diabetes mellitus -	_	0.90 (0.74–1.09)	0.29	-	1.03 (0.81–1.31)	0.82
Atrial fibrillation or flutter	•	1.07 (0.89–1.30)	0.46		1.01 (0.80–1.27)	0.95
Prior myocardial infarction	_	0.93 (0.74–1.16)	0.51		0.92 (0.70–1.21)	0.55
Prior stroke	—	1.86 (1.49–2.33)	<0.001	—	1.67 (1.28–2.19)	<0.001
Chronic lung disease	-	1.07 (0.82–1.40)	0.61		1.13 (0.83–1.55)	0.43
Dementia		3.05 (2.48–3.76)	<0.001	—	2.26 (1.74–2.95)	<0.001
Current smoking -		0.35 (0.23–0.51)	<0.001	-	0.55 (0.35–0.86)	0.009
Living alone	•	1.15 (0.93–1.43)	0.20		1.14 (0.87–1.48)	0.34
Ambulatory before admission -		0.77 (0.61–0.97)	<0.001	—	1.74 (1.29–2.35)	<0.001
Systolic BP <90 mmHg		0.91 (0.49–1.68)	0.76		0.62 (0.26–1.45)	0.26
Heart rate <60 beat/min	•	1.33 (0.95–1.87)	0.10		1.12 (0.74–1.68)	0.60
Body temperature ≥37.5 °C	- _	2.30 (1.67–3.16)	<0.001		1.91 (1.31–2.79)	<0.001
NYHA class III or IV		1.81 (1.30–2.51)	<0.001		1.54 (1.07–2.22)	0.02
LVEF <40%		0.76 (0.62–0.92)	0.006		1.12 (0.88–1.44)	0.35
Anaemia	_	1.74 (1.41–2.16)	<0.001		1.13 (0.86–1.47)	0.38
Albumin <3.0 g/dL	_	2.16 (1.71–2.75)	<0.001	—	1.76 (1.32–2.34)	<0.001
Sodium <135 mEq/L	—	1.55 (1.19–2.01)	0.001	_	1.49 (1.10–2.03)	0.01
eGFR <30 ml/min/1.73m ²	—	1.79 (1.47–2.18)	<0.001	—	1.55 (1.22–1.98)	<0.001
1.	0 2.0 3.0 4.0			1.0 2.0 3.0		

Figure 2 Clinical factors associated with functional decline during hospitalisation in the univariate and multivariable logistic regression models. BP, blood pressure; BMI, body mass index; eGFR, estimated glomerular filtration rate; HF, heart failure; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association.

higher than that in the no functional decline group (49%) vs 31%, log-rank p<0.001) (figure 3). After adjusting for baseline characteristics, the higher risk of the functional decline group relative to the no functional decline group remained significant (adjusted HR, 1.46; 95% CI, 1.24 to 1.71; p<0.001) (figure 3 and table 3). The cumulative 1-year incidence of all-cause death was also significantly higher in the functional decline group than in the no functional decline group. Even after adjusting for confounders, the excess mortality risk of the functional decline group relative to the no functional decline group remained significant (figure 3 and table 3). The cumulative 1-year incidence of heart failure hospitalisation was also significantly higher in the functional decline group than in the no functional decline group. However, the adjusted risk of the functional decline group relative to the no functional decline group for heart failure hospitalisation was no longer significant (figure 3 and table 3). The cumulative 1-year incidence of a composite of all-cause death or all-cause hospitalisation was significantly higher in the functional decline

group than in the no functional decline group. After adjusting for confounders, the higher risk of the functional decline group relative to the no functional decline group remained significant (figure 3 and table 3). In the subgroup analyses, there were no interactions between those subgroup factors and the association of functional decline with the primary outcome measure (online supplementary eFigure 2).

Additional analysis on the risk factors for functional decline or in-hospital mortality

The risk factors for functional decline or in-hospital mortality in a total of 4056 patients were similar to the risk factors for functional decline. LVEF <40% (OR 1.24; 95% CI 1.00 to 1.52; p=0.047) and acute coronary syndrome (OR 1.76; 95% CI 1.19 to 2.60; p=0.005) which were not included as risk factors for functional decline emerged as risk factors for functional decline or in-hospital mortality (online supplementary eTable 2). Meanwhile, among the risk factors for functional decline, being female (OR 1.13; 95% CI 0.93 to 1.38; p=0.22) was not included as a risk factor

Table 2 In-hospital management and outcome				
	Functional decline	No functional decline		
	n=528	n=3027	P value	
In-hospital manage	ement			
Management in t room	he emergency	,		
Respiratory ma	anagement			
Oxygen inhalation	295 (56)	1382 (46)	<0.001	
NIPPV	82 (16)	423 (14)	0.35	
Intubation	11 (2.1)	53 (1.8)	0.60	
Intravenous drug presentation	ıs within 24 ho	urs after hospital		
Inotropes	101 (19)	405 (13)	<0.001	
Furosemide	446 (85)	2536 (84)	0.69	
In-hospital clinical outcomes				
In-hospital adver	rse events			
Stroke	27 (5.1)	26 (0.9)	< 0.001	
Worsening heart failure	130 (25)	490 (16)	<0.001	
Worsening renal function	244 (47)	992 (33)	<0.001	
In-hospital infection	104 (20)	258 (8.5)	<0.001	
Length of stay, days	21 (14–37)	15 (11–22)	<0.001	

NIPPV, non-invasive intermittent positive pressure ventilation.

for functional decline or in-hospital mortality (figure 2 and online supplementary eTable 2).

DISCUSSION

The main findings of the present study investigating the prevalence and risk factors of functional decline during hospitalisation and its relationship with postdischarge outcomes in patients with ADHF hospitalisation were as follows: (1) functional decline during ADHF hospitalisation occurred in 15% of patients, and 80% of those with functional decline were ambulatory before admission; (2) the independent baseline risk factors associated with functional decline included age ≥ 80 years, female, prior stroke, dementia, ambulatory before admission, elevated body temperature, New York Heart Association class III or IV on admission, decreased albumin levels, hyponatraemia and renal dysfunction; and (3) functional decline during the index hospitalisation was associated with higher long-term risk for a composite of all-cause death or heart failure hospitalisation.

This is the first, large-scale, contemporary, multicentre study reporting the prevalence of functional decline in patients hospitalised for ADHF. Of note, we identified the





Figure 3 Cumulative incidence for the primary outcome measure (A), all-cause death (B), HF hospitalisation (C), and a composite of all-cause death or all-cause hospitalisation (D), according to the presence or absence of functional decline. HF, heart failure.

severity of symptoms or patient status specific for heart failure was associated with functional decline independent of well-known factors in acute medical illness.¹⁸⁻²⁰ Functional decline is an inevitable consequence in aged people, but hospitalisation accelerates the decline.20-22 Functional declines have been found to be related not only to impairment of independence and quality of life (QOL), but also to increased health service use, higher risk for institutionalisation and higher risk for mortality.^{23–27} Indeed, in the present study, the proportion of patients discharged to home was lower in the functional decline group than in the no functional decline group, suggesting impaired QOL after discharge. Also, long-term mortality was worse in the functional decline group than in the no functional decline group. Therefore, it is important to recognise risk factors of functional decline. In previous studies of hospitalised patients with acute medical illness, the predictors of functional decline in hospitalised elderly patients were older age, admission diagnosis, lower functional status, impaired cognitive status, comorbidities and length of hospital stay.¹⁸⁻²⁰ These findings were confirmed in the setting of ADHF in our present study. In addition, findings specific for ADHF such as the dyspnoea or hyponatraemia were associated with functional decline, which were also reported to be risk factors for in-hospital mortality in ADHF.²⁸ The prevalence of oedema and general malaise at discharge was

Table 3 Clinical outcomes in the entire cohort						
	Functional decline	No functional e decline				
Outcomes	Patients with event (n)/patients at risk (N) (cumulative 1- year incidence, %)	Patients with event (n)/patients at risk (N) (cumulative 1- year incidence, %))	Unadjusted HR (95% CI)	P value	Adjusted HR (95% CI)	P value
All-cause death or HF hospitalisation	243/528 (49)	902/3027 (31)	1.95 (1.71 to 2.21)	<0.001	1.46 (1.24 to 1.71)	<0.001
All-cause death	174/528 (36)	386/3027 (13)	3.02 (2.58 to 3.53)	<0.001	2.12 (1.74 to 2.58)	<0.001
HF hospitalisation	116/528 (28)	663/3027 (23)	1.25 (1.04 to 1.50)	0.02	1.03 (0.83 to 1.28)	0.81
All-cause death or all- cause hospitalisation	279/528 (57)	1186/3027 (40)	1.69 (1.50 to 1.91)	<0.001	1.39 (1.20 to 1.61)	<0.001

The number of patients with at least one event was counted through the 1-year follow-up period. HF, heart failure.

higher in the functional decline group. Early achievement of successful ADHF treatment might reduce the risk of functional decline, although the present observational study could not address the cause–effect relationship between the functional decline and the symptomatic status at discharge.

There might be several possible strategies to prevent functional decline during ADHF hospitalisation. The first is the early improvement of haemodynamic status to avoid worsening heart failure. The prevalence of worsening heart failure was higher in the functional decline group. As functional decline associated with hospitalisation begins within 48 hours of admission, early improvement of heart failure to reduce the incidence of hospitalisationassociated disability is one of the main goals of care.²⁸ Second, it would be important to be adequately aware that providing aggressive interventions prevents functional decline in high-risk patients. We identified the risk factors among the baseline characteristics in patients with ADHF. In addition, the adverse events during hospitalisation may be tightly related to the functional decline. Stroke is one of the causes of functional decline and is observed in 5.1% of patients with functional decline. Third, seamless rehabilitation and comprehensive geriatric management through a multidisciplinary team approach might be a strategy for the prevention of functional decline.^{29–32} In addition, the subgroup analysis showed that there were no interactions between those subgroup factors and the association of functional decline with the primary outcome measure. Thus, prevention of functional decline would have an impact on improving outcomes in all patients with ADHF. One possible strategy could be immediate, tailored physical function rehabilitation during and after heart failure hospitalisation.³³

Limitations

This study has several limitations. First, we adopted simple classification of functional status based on the definition of the Japanese long-term care insurance: ambulatory, use of wheelchair outdoor only, use of wheelchair indoor and outdoor, and bedridden state. The categorisation scheme is an easy-to-understand but coarse measure with very large gradations inherent in each single stage and therefore very likely substantially underestimated the prevalence of meaningful functional decline. Second, we did not collect data regarding on-site and outpatient rehabilitation and nutritional support. However, a team-based approach for patients with heart failure was adapted in all the participating centres in the present study. Third, we did not include the status at discharge or adverse in-hospital events in the analysis for the risk factor for functional decline, because the cause-effect relationship was not clear. Fourth, data on postdischarge medication and change of functional status after discharge from the index hospitalisation were not collected and not analysed in the analysis for the long-term outcomes. Fifth, as with any observational study, the possibility of selection bias and residual confounding cannot be excluded, although we adjusted for 29 variables as most conceivable confounders.

CONCLUSIONS

The independent risk factors of functional decline in patients with ADHF were related to both frailty and severity of heart failure. Functional decline during ADHF hospitalisation was associated with unfavourable postdischarge outcomes.

Author affiliations

 ¹Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine and Faculty of Medicine, Kyoto, Japan
²Department of Cardiology, Mitsubishi Kyoto Hospital, Kyoto, Japan
³Clinical Epidemiology, Hyogo College of Medicine, Nishinomiya, Japan
⁴Cardiovascular Medicine, Shiga General Hospital, Moriyama, Japan
⁵Cardiology, Public Interest Incorporated Foundation Tenri Hospital, Tenri, Japan
⁶Cardiovascular Medicine, Kobe City Medical Center General Hospital, Kobe, Japan
⁷Department of Cardiology, Hikone Municipal Hospital, Hikone, Japan
⁸Cardiovascular Medicine, Shiga University of Medical Science, Otsu, Japan
⁹Cardiology, Hyogo Prefectural Amagasaki General Medical Center, Amagasaki, Japan

¹⁰Cardiovascular Medicine, Shinshu University Graduate School of Medicine, School of Medicine, Matsumoto, Japan

sity.

9

Acknowledgements We gratefully acknowledge the contributions of the KCHF study investigators: Hidenori Yaku MD, Takao Kato MD, Neiko Ozasa MD, Erika Yamamoto MD, Yusuke Yoshikawa MD, Tetsuo Shioi MD, Koichiro Kuwahara MD, Takeshi Kimura MD, at Kyoto University Hospital, Kyoto, Japan; Moritake Iguchi MD, Yugo Yamashita MD, Masaharu Akao MD, at National Hospital Organization Kyoto Medical Center, Kyoto, Japan; Masashi Kato MD, Shinji Miki MD, at Mitsubishi Kyoto Hospital, Kyoto, Japan; Mamoru Takahashi MD, at Shimabara Hospital, Kyoto, Japan; Tsuneaki Kawashima MD, Takafumi Yagi MD, at Okamoto Memorial Hospital; Toshikazu Jinnai MD, Takashi Konishi MD, at Japanese Red Cross Otsu Hospital, Otsu, Japan: Yasutaka Inuzuka MD, Shigeru Ikeguchi MD, at Shiga General Hospital, Moriyama, Japan; Tomoyuki Ikeda MD, Yoshihiro Himura MD, at Hikone Municipal Hospital, Hikone, Japan; Kazuya Nagao MD, Tsukasa Inada MD, at Osaka Red Cross Hospital, Osaka, Japan; Kenichi Sasaki MD, Moriaki Inoko MD, at Kitano Hospital, Osaka, Japan; Takafumi Kawai MD, Tomoki Sasa MD, Mitsuo Matsuda MD, at Kishiwada City Hospital, Kishiwada, Japan; Akihiro Komasa MD, Katsuhisa Ishii MD, at Kansai Electric Power Hospital, Osaka, Japan; Yodo Tamaki MD, Yoshihisa Nakagawa MD, at Tenri Hospital, Tenri, Japan; Ryoji Taniguchi MD, Yukihito Sato MD. Yoshiki Takatsu MD. at Hvogo Prefectural Amagasaki General Medical Center. Amagasaki, Japan; Takeshi Kitai MD, Ryousuke Murai MD, Yutaka Furukawa MD, at Kobe City Medical Center General Hospital, Kobe, Japan; Mitsunori Kawato MD, at Kobe City Nishi-Kobe Medical Center, Kobe, Japan; Yasuyo Motohashi MD, Kanae Su MD, Mamoru Toyofuku MD, Takashi Tamura MD, at Japanese Red Cross Wakayama Medical Center, Wakayama, Japan; Reiko Hozo MD, Ryusuke Nishikawa MD, Hiroki Sakamoto MD, at Shizuoka General Hospital, Shizuoka, Japan; Yuichi Kawase MD, Keiichiro Iwasaki MD, Kazushige Kadota MD, at Kurashiki Central Hospital, Kurashiki, Japan; and Takashi Morinaga MD, Yohei Kobayashi MD, Kenji Ando MD, at Kokura Memorial Hospital, Kokura, Japan.

Contributors HY and TKa had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Concept and design: HY, TKa, TM, YT, NO, EY, TKit, MK, TKim. Acquisition, analysis or interpretation of data: HY, TKa, TM, YI, YT, YY, TI, YF, KK. Drafting of the manuscript: HY, TKa, TKim. Critical revision of the manuscript for important intellectual content: HY, TKa, TM, YI, YT, YY, TKit, KK, TKim. Statistical analysis: HY, TKa, TM. Administrative, technical or material support: TKa, YS, TKim. Supervision: YI, NO, TKi, YF, YN, YS, KK, TKim.

Funding This study is supported by a grant from the Japan Agency for Medical Research and Development (18059186) to TKa, KK and NO.

Competing interests None declared.

Patient consent for publication Not required.

Ethics approval The study was approved by the institutional review boards of Kyoto University Graduate School of Medicine (approval number: E2311), Shiga General Hospital (approval number: 20141120-01), Tenri Hospital (approval number: 640), Kobe City Medical Center General Hospital (approval number: 14094), Hyogo Prefectural Amagasaki General Medical Center (approval number: Rinri 26-32), National Hospital Organization Kyoto Medical Center (approval number: 14-080), Mitsubishi Kyoto Hospital (approved 11/12/2014), Okamoto Memorial Hospital (approval number: 201503), Japanese Red Cross Otsu Hospital (approval number: 318), Hikone Municipal Hospital (approval number: 26-17), Japanese Red Cross Osaka Hospital (approval number: 392), Shimabara Hospital (approval number: E2311), Kishiwada City Hospital (approval number: 12), Kansai Electric Power Hospital (approval number: 26-59), Shizuoka General Hospital (approval number: Rin14-11-47), Kurashiki Central Hospital (approval number: 1719), Kokura Memorial Hospital (approval number: 14111202), Kitano Hospital (approval number: P14-11-012), and Japanese Red Cross Wakayama Medical Center (approval number: 328). A waiver of written informed consent from each patient was granted by the institutional review boards of Kyoto University and each participating centre.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement All data relevant to the study are included in the article or uploaded as supplementary information. No additional data available.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iDs

Takao Kato http://orcid.org/0000-0001-8213-7999 Takeshi Morimoto http://orcid.org/0000-0002-6844-739X

REFERENCES

- Manton KG. A longitudinal study of functional change and mortality in the United States. J Gerontol 1988;43:S153–61.
- 2 Boyd CM, Ricks M, Fried LP, et al. Functional decline and recovery of activities of daily living in hospitalized, disabled older women: the women's health and aging study I. J Am Geriatr Soc 2009;57:1757–66.
- 3 Guralnik JM, Alecxih L. Medical and long-term care costs when older persons become more dependent intentional weight loss and 13-year diabetes incidence in overweight adults. *Am J Public Health* 2002;92:1244–5.
- 4 Gill TM, Allore HG, Holford TR, et al. Hospitalization, restricted activity, and the development of disability among older persons. JAMA 2004;292:2115–24.
- 5 Sager MA, Franke T, Inouye SK, *et al.* Functional outcomes of acute medical illness and hospitalization in older persons. *Arch Intern Med* 1996;156:645–52.
- 6 Ethical guidelines for epidemiologic research. Ministry of Education, Culture, Sports, Science and Technology Ministry of Health L and W. Japan's, 2002. Available: http://www.lifescience.mext.go.jp/files/pdf/ n796_01.pdf
- 7 45 Code of Federal Regulations 46.116(d), 2009. Available: https:// www.hhs.gov/ohrp/regulations-and-policy/regulations/45-cfr-46/ index.html#46.116
- 8 Yamamoto E, Kato T, Ozasa N, et al. Kyoto congestive heart failure (KCHF) study: rationale and design. ESC Heart Fail 2017;4:216–23.
- 9 Yaku H, Ozasa N, Morimoto T, et al. Demographics, Management, and In-Hospital Outcome of Hospitalized Acute Heart Failure Syndrome Patients in Contemporary Real Clinical Practice in Japan - Observations From the Prospective, Multicenter Kyoto Congestive Heart Failure (KCHF) Registry. *Circ J* 2018;82:2811–9.
- 10 Yaku H, Kato T, Morimoto T, et al. Association of mineralocorticoid receptor antagonist use with all-cause mortality and hospital readmission in older adults with acute decompensated heart failure. JAMA Netw Open 2019;2:e195892–14.
- 11 Su K, Kato T, Toyofuku M, et al. Association of previous hospitalization for heart failure with increased mortality in patients hospitalized for acute decompensated heart failure. *Circ Rep* 2019;1:517–24.
- 12 Butler J, Gheorghiade M, Kelkar A, et al. In-Hospital worsening heart failure. Eur J Heart Fail 2015;17:1104–13.
- 13 Filippatos G, Farmakis D, Parissis J. Renal dysfunction and heart failure: things are seldom what they seem. *Eur Heart J* 2014;35:416–8.
- 14 Vardeny O, Wu DH, Desai A, et al. Influence of baseline and worsening renal function on efficacy of spironolactone in patients with severe heart failure: insights from RALES (randomized Aldactone evaluation study). J Am Coll Cardiol 2012;60:2082–9.
- 15 Clark H, Krum H, Hopper I. Worsening renal function during reninangiotensin-aldosterone system inhibitor initiation and long-term outcomes in patients with left ventricular systolic dysfunction. *Eur J Heart Fail* 2014;16:41–8.
- 16 Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016;37.
- 17 Oda E, Oohara K, Abe A, et al. The optimal cut-off point of C-reactive protein as an optional component of metabolic syndrome in Japan. *Circ J* 2006;70:384–8.
- 18 Stuck AE, Walthert JM, Nikolaus T, et al. Risk factors for functional status decline in community-living elderly people: a systematic literature review. Soc Sci Med 1999;48:445–69.
- 19 McCusker J, Kakuma R, Abrahamowicz M. Predictors of functional decline in hospitalized elderly patients: a systematic review. J Gerontol A Biol Sci Med Sci 2002;57:M569–77.
- 20 Covinsky KE, Palmer RM, Fortinsky RH, et al. Loss of independence in activities of daily living in older adults hospitalized with medical illnesses: increased vulnerability with age. J Am Geriatr Soc 2003;51:451–8.
- 21 Inouye SK, Bogardus ST, Baker DI, et al. The hospital elder life program: a model of care to prevent cognitive and functional decline in older hospitalized patients. Hospital elder life program. J Am Geriatr Soc 2000;48:1697–706.
- 22 Pandharipande PP, Girard TD, Jackson JC, et al. Long-Term cognitive impairment after critical illness. N Engl J Med 2013;369:1306–16.
- 23 Hirvensalo M, Rantanen T, Heikkinen E. Mobility difficulties and physical activity as predictors of mortality and loss of independence in the community-living older population. *J Am Geriatr Soc* 2000;48:493–8.

Open access

- 24 Greiner PA, Snowdon DA, Schmitt FA. The loss of independence in activities of daily living: the role of low normal cognitive function in elderly nuns. *Am J Public Health* 1996;86:62–6.
- 25 Ganguli M, Seaberg E, Belle S, et al. Cognitive impairment and the use of health services in an elderly rural population: the movies project. Monongahela Valley independent elders survey. J Am Geriatr Soc 1993;41:1065–70.
- 26 Barberger-Gateau P, Fabrigoule C. Disability and cognitive impairment in the elderly. *Disabil Rehabil* 1997;19:175–93.
- 27 Black SA, Rush RD. Cognitive and functional decline in adults aged 75 and older. *J Am Geriatr Soc* 2002;50:1978–86.
- 28 Hirsch CH, Sommers L, Olsen A, *et al*. The natural history of functional morbidity in hospitalized older patients. *J Am Geriatr Soc* 1990;38:1296–303.

- 29 O'Connor CM, Whellan DJ, Lee KL, *et al.* Efficacy and safety of exercise training in patients with chronic heart failure: HF-ACTION randomized controlled trial. *JAMA* 2009;301:1439–50.
- 30 Baztán JJ, Suárez-García FM, López-Arrieta J, et al. Effectiveness of acute geriatric units on functional decline, living at home, and case fatality among older patients admitted to hospital for acute medical disorders: meta-analysis. *BMJ* 2009;338:b50–6.
- 31 Fox MT, Persaud M, Maimets I, et al. Effectiveness of acute geriatric unit care using acute care for elders components: a systematic review and meta-analysis. J Am Geriatr Soc 2012;60:2237–45.
- 32 Bachmann S, Finger Ć, Huss A, et al. Inpatient rehabilitation specifically designed for geriatric patients: systematic review and meta-analysis of randomised controlled trials. BMJ 2010;340:c1718.
- 33 Reeves GR, Whellan DJ, Duncan P, et al. Rehabilitation therapy in older acute heart failure patients (REHAB-HF) trial: design and rationale. Am Heart J 2017;185:130–9.